NASH、肝纤维化、动脉粥样硬化等炎症相关重大慢病的药理学研究
1．侧重从调控细胞及组织微环境角度开展抗NASH、抗肝纤维化的天然药物及衍生物的发现及作用机制研究。
2. 基于分子和细胞水平的多维高通量筛选模型构建策略，发现治疗代谢性疾病以及心血管疾病的新型小分子药物。
3. 靶向代谢性疾病重要核受体，如LXR/FXR/PPARs等的小分子药物的药理学研究。

1. Validation of baicalein and oridonin as nonspecific SARS-CoV-2 main protease inhibitors. Yan H#, Zhang R#, Yan G, Liu X, Li N*, Chen Y*. Phytotherapy Research, 2023.
2. LXR agonist inhibits inflammation through regulating MyD88 mRNA alternative splicing. Li N#, Li Y#, Han X, Zhang J, Han J, Jiang X, Wang W, Xu Y, Xu Y, Fu Y*, Si S*. Frontiers in Pharmacology, 2022.
3. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. Li N#, Wang X#, Xu Y, Lin Y, Zhu N, Liu P, Lu D*, Si S*. Molecular Pharmacology, 2017.
4. E17110 promotes reverse cholesterol transport with liver X receptor β agonist activity in vitro. Li N#, Wang X, Liu P, Lu D, Jiang W, Xu Y*, Si S*. Acta Pharmaceutica Sinica B. 2016.
5. Identification of a novel partial agonist of liver X receptor α (LXRα) via screening. Li N#, Wang X, Zhang J, Liu C, Li Y, Feng T, Xu Y*, Si S*. Biochemical Pharmacology. 2014.
6. Identification of a selective agonist for Liver X Receptor α (LXRα) via screening of a synthetic compound library. Li N#, Xu Y, Feng T, Liu C, Li Y, Wang X, Si S*. Journal of Biomolecular Screening. 2014.